Piramal brings expanded sterile-product testing infrastructure online in Lexington
Company / institutional announcement · Piramal Pharma Solutions / PR Newswire
Source published: · Event / reporting date: 2026-09-11
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Piramal announced that its new Lexington microbiology laboratory entered routine GMP use on September 11, with the sterility suite subsequently conditionally approved. The lab expands testing space and adds a Grade A isolator intended to double sterility-testing capacity. It is an early component of an $85 million sterile-injectables expansion; the remaining manufacturing capacity is expected in late 2027.
Why it may matter
Sterility testing and batch release can constrain fill-finish growth, underscoring why drug product capacity needs matching quality infrastructure and laboratory throughput.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections